Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dicloxacillin Sodium

FDA-approved product (capsule, oral), marketed as Dicloxacillin Sodium, Dycill, Dynapen and 1 more.

Registered studies
17
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Dicloxacillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase resistant penicillins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CF01

Repurposing investigation

Dicloxacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli26.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae50.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

17registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dicloxacillin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dicloxacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria

    NCT00037050 · start 2002-04

    Registered record
    Registry ID
    NCT00037050
    Conditions
    Bacterial Infections; Gram-Positive Bacterial Infections; Bacteremia
    Interventions
    Linezolid; Vancomycin; Oxacillin; Dicloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-04
    Completion
    2005-07
    Enrolment
    739

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections; Gram-Positive Bacterial Infections; Bacteremia
    InterventionLinezolid; Vancomycin; Oxacillin; Dicloxacillin
    PhasePhase 3
    Registry statusCompleted

  • Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia

    NCT07186894 · start 2000-01-01

    Registered record
    Registry ID
    NCT07186894
    Conditions
    Bacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
    Interventions
    Antistaphylococcal penicillins; Cefazolin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2000-01-01
    Completion
    2026-09-01
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
    InterventionAntistaphylococcal penicillins; Cefazolin
    PhaseNot recorded
    Registry statusActive not recruiting